Compare TG Therapeutics Inc (TGTX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Victoria's Secret & Co — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Victoria's Secret & Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Victoria's Secret & Co for 34 Days on average.
| TGTX | VSXY | |
|---|---|---|
Market Cap | $8.16B | $6.91B |
Volume | 1,735,121 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $99.97 |
52-Week Low | $26.94 | $28.25 |
Typical Hold Time | 16 Days | 34 Days |
Enterprise Value | $8.37B | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with three consecutive earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy driving international growth.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, though rich valuation (P/E 19.33) and rising costs present risks. Key catalysts include sustained margin improvement and global expansion execution, while competition and demand volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
